title: A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.
authors: Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California 94305, USA.
authors: Jonathan W
authors: JW
authors: Riess
authors: Seema
authors: S
authors: Nagpal
authors: Millie
authors: M
authors: Das
authors: Joel W
authors: JW
authors: Neal
authors: Jonathan W
authors: JW
authors: Kim
authors: Heather A
authors: HA
authors: Wakelee
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy; D002830:Choroid Neoplasms / Q000556:secondary / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D000068437:Pemetrexed; D011379:Prognosis; D014786:Vision Disorders / Q000517:prevention & control*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005971:Glutamates; D000068437:Pemetrexed; D000068258:Bevacizumab; D006147:Guanine; D002945:Cisplatin